Trial Profile
A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms AURIEL-PsO
- Sponsors EMD Serono; Merck KGaA
- 17 Jun 2019 Results published in the British Journal of Dermatology
- 22 May 2019 Results assessing quality of life outcomes of MSB11022 versus reference adalimumab presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 03 Apr 2019 According to a Fresenius Kabi media release, the European Commission (EC) granted marketing authorization for IDACIO, an adalimumab biosimilar, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis including ankylosing spondylitis, psoriatic arthritis, adult and paediatric, plaque psoriasis, adult and adolescent hidradenitis suppurativa, adult and paediatric Crohn's disease, ulcerative colitis, adult and paediatric noninfectious uveitis4.